Evidence map›Paper›PMID 30540745›Full record

ArticlePloS one2018

Screen for modulators of atonal homolog 1 gene expression using notch pathway-relevant gene transcription based cellular assays.

Xin Zeng, Robert Kirkpatrick, Glenn Hofmann, Didier Grillot, Valerie Linhart, Fabrice Viviani, Joseph Marino, Joseph Boyer, Taylor L Graham, Quinn Lu and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Xin ZengR&D Target Sciences, GlaxoSmithKline, Upper Providence, Collegeville, United States of America.ORCID 0000-0003-2098-4580
Robert KirkpatrickR&D Alternative Discovery and Development, GlaxoSmithKline, Upper Providence, Collegeville, United States of America.ORCID 0000-0002-8671-2361
Glenn HofmannR&D Platform Technology Sciences, Drug Design and Selection, GlaxoSmithKline, Upper Providence, Collegeville, United States of America.
Didier GrillotR&D Flexible Discovery Unit, Villebon-sur-Yvette, Paris, France.
Valerie LinhartR&D Flexible Discovery Unit, Villebon-sur-Yvette, Paris, France.
Fabrice VivianiR&D Flexible Discovery Unit, Villebon-sur-Yvette, Paris, France.
Joseph MarinoR&D Alternative Discovery and Development, GlaxoSmithKline, Upper Providence, Collegeville, United States of America.
Joseph BoyerR&D Statistical sciences, GlaxoSmithKline, Upper Providence, Collegeville, United States of America.
Taylor L GrahamR&D Target Sciences, GlaxoSmithKline, Upper Providence, Collegeville, United States of America.
Quinn LuR&D Target Sciences, GlaxoSmithKline, Upper Providence, Collegeville, United States of America.
Zining WuR&D Platform Technology Sciences, Drug Design and Selection, GlaxoSmithKline, Upper Providence, Collegeville, United States of America.
Andrew BenowitzR&D Alternative Discovery and Development, GlaxoSmithKline, Upper Providence, Collegeville, United States of America.
Rick CousinsR&D Alternative Discovery and Development, GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom.
Providence College · USTarget (United States) · USGlaxoSmithKline (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atonal homolog 1 (Atoh1) is a basic helix-loop-helix 9 (bHLH) transcription factor acting downstream of Notch and is required for the differentiation of sensory hair cells in the inner ear and the specification of secretory cells during the intestinal crypt cell regeneration. Motivated by the observations that the upregulation of Atoh1 gene expression, through genetic manipulation or pharmacological inhibition of Notch signaling (e.g. γ-secretase inhibitors, GSIs), induces ectopic hair cell growth in the cochlea of the inner ear and partially restores hearing after injuries in experimental models, we decided to identify small molecule modulators of the Notch-Atoh1 pathway, which could potentially regenerate hair cells. However, the lack of cellular models of the inner ear has precluded the screening and characterization of such modulators. Here we report using a colon cancer cell line LS-174T, which displays Notch inhibition-dependent Atoh1 expression as a surrogate cellular model to screen for inducers of Atoh1 expression. We designed an Atoh1 promoter-driven luciferase assay to screen a target-annotated library of ~6000 compounds. We further developed a medium throughput, real-time quantitative RT-PCR assay measuring the endogenous Atoh1 gene expression to confirm the hits and eliminate false positives from the reporter-based screen. This strategy allowed us to successfully recover GSIs of known chemotypes. This LS-174T cell-based assay directly measures Atoh1 gene expression induced through Notch-Hes1 inhibition, and therefore offers an opportunity to identify novel cellular modulators along the Notch-Atoh1 pathway.

Indexed as

Basic Helix-Loop-Helix ProteinsBenzodiazepinesCell Line, TumorGene ExpressionGenes, ReporterHumansMicroscopy, FluorescencePromoter Regions, GeneticReceptors, NotchSignal TransductionSmall Molecule LibrariesTranscription Factor HES-1ATOH1 protein, humanBasic Helix-Loop-Helix ProteinsBenzodiazepinesHES1 protein, humanReceptors, NotchSmall Molecule LibrariesTranscription Factor HES-1

Identifiers

PMID30540745
PMCPMC6291236
OpenAlexW2903933165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.